middle.news

How Microba’s 30% Revenue Surge Fuels UK Expansion and Diagnostic Innovation

11:40pm on Friday 29th of August, 2025 AEST Healthcare
Read Story

How Microba’s 30% Revenue Surge Fuels UK Expansion and Diagnostic Innovation

11:40pm on Friday 29th of August, 2025 AEST
Key Points
  • 30% revenue growth to $15.7 million in FY25
  • Net loss narrowed to $14.9 million from $19.9 million in FY24
  • Successful UK expansion through Invivo Clinical acquisition
  • Discontinuation of legacy products to focus on core diagnostics
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Microba Life Sciences (ASX:MAP)
OPEN ARTICLE